Second, the stimulation of sodium–iodide symporter (NIS) expression in thyroid cancer patients before I-131 administration could increase NIS expression in the breast, resulting in an elevated risk of breast cancer. Here, SLC5A5 is linked to thyroid gland carcinoma.